Zacks Investment Research downgraded shares of PLURISTEM THERA (PSTI) from OUTPERFORM to NEUTRAL on January 06, 2015, with a target price of $3.10.
PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on PLURISTEM THERA (PSTI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment